{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T21:13:49Z","timestamp":1788470029744,"version":"build-2803163510"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,1,2]],"date-time":"2021-01-02T00:00:00Z","timestamp":1609545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,2]],"date-time":"2021-01-02T00:00:00Z","timestamp":1609545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP19K176974"],"award-info":[{"award-number":["JP19K176974"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Osaka Foundation for The Prevention of Cancer and Lifestyle-related Diseases"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s12282-020-01200-1","type":"journal-article","created":{"date-parts":[[2021,1,2]],"date-time":"2021-01-02T22:02:22Z","timestamp":1609624942000},"page":"765-771","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["STK11 loss drives rapid progression in a breast cancer patient resulting in pulmonary tumor thrombotic microangiopathy"],"prefix":"10.1007","volume":"28","author":[{"given":"Fumie","family":"Fujisawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5241-3486","authenticated-orcid":false,"given":"Kei","family":"Kunimasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rieko","family":"Kano-Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiharu","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Kusama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minako","family":"Nishio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saki","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuhiro","family":"Yoshinami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyoshi","family":"Kittaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harumi","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigenori","family":"Nagata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichiro","family":"Honma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshinari","family":"Yagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Tamaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumio","family":"Imamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,2]]},"reference":[{"key":"1200_CR1","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1002\/1097-0142(19900801)66:3<587::AID-CNCR2820660330>3.0.CO;2-J","volume":"66","author":"A von Herbay","year":"1990","unstructured":"von Herbay A, Illes A, Waldherr R, Otto HF. Pulmonary tumor thrombotic microangiopathy with pulmonary hypertension. Cancer. 1990;66:587\u201392.","journal-title":"Cancer"},{"key":"1200_CR2","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1200\/JCO.2006.09.0670","volume":"25","author":"S Miyano","year":"2007","unstructured":"Miyano S, Izumi S, Takeda Y, et al. Pulmonary tumor thrombotic microangiopathy. J Clin Oncol. 2007;25:597\u20139.","journal-title":"J Clin Oncol"},{"key":"1200_CR3","doi-asserted-by":"publisher","first-page":"204589401985100","DOI":"10.1177\/2045894019851000","volume":"9","author":"RH Godbole","year":"2019","unstructured":"Godbole RH, Saggar R, Kamangar N. Pulmonary tumor thrombotic microangiopathy: a systematic review. Pulm Circ. 2019;9:2045894019851000.","journal-title":"Pulm Circ"},{"key":"1200_CR4","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1186\/s12885-016-2721-3","volume":"16","author":"Y Takahashi","year":"2016","unstructured":"Takahashi Y, Uruga H, Fujii T, et al. Antemortem diagnosis of pulmonary tumor thrombotic microangiopathy in a patient with recurrent breast cancer: a case report. BMC Cancer. 2016;16:666.","journal-title":"BMC Cancer"},{"key":"1200_CR5","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1164\/rccm.201503-0605LE","volume":"192","author":"P Salinas","year":"2015","unstructured":"Salinas P, Manning H. The Role of Immunohistochemistry in Diagnosis of Pulmonary Tumor Thrombotic Microangiopathy. Am J Respir Crit Care Med. 2015;192:116.","journal-title":"Am J Respir Crit Care Med"},{"key":"1200_CR6","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41571-018-0002-6","volume":"15","author":"MF Berger","year":"2018","unstructured":"Berger MF, Mardis ER. The emerging clinical relevance of genomics in cancer medicine. Nat Rev Clin Oncol. 2018;15:353\u201365.","journal-title":"Nat Rev Clin Oncol"},{"key":"1200_CR7","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.cell.2016.12.015","volume":"168","author":"DM Hyman","year":"2017","unstructured":"Hyman DM, Taylor BS, Baselga J. Implementing genome-driven oncology. Cell. 2017;168:584\u201399.","journal-title":"Cell"},{"key":"1200_CR8","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61\u201370.","DOI":"10.1038\/nature11412"},{"key":"1200_CR9","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1158\/2159-8290.CD-18-1177","volume":"9","author":"AC Garrido-Castro","year":"2019","unstructured":"Garrido-Castro AC, Lin NU, Polyak K. Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment. Cancer Discov. 2019;9:176\u201398.","journal-title":"Cancer Discov"},{"key":"1200_CR10","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.molcel.2015.10.031","volume":"60","author":"S Koren","year":"2015","unstructured":"Koren S, Bentires-Alj M. Breast tumor heterogeneity: source of fitness hurdle for therapy. Mol Cell. 2015;60:537\u201346.","journal-title":"Mol Cell"},{"key":"1200_CR11","doi-asserted-by":"crossref","unstructured":"Chakravarty D, Gao J, Phillips SM et al. OncoKB: A Precision Oncology Knowledge Base. JCO Precis Oncol 2017;2017.","DOI":"10.1200\/PO.17.00011"},{"key":"1200_CR12","doi-asserted-by":"publisher","first-page":"3055","DOI":"10.1111\/cas.13746","volume":"109","author":"M Liu","year":"2018","unstructured":"Liu M, Jiang L, Fu X, et al. Cytoplasmic liver kinase B1 promotes the growth of human lung adenocarcinoma by enhancing autophagy. Cancer Sci. 2018;109:3055\u201367.","journal-title":"Cancer Sci"},{"key":"1200_CR13","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nrc2676","volume":"9","author":"DB Shackelford","year":"2009","unstructured":"Shackelford DB, Shaw RJ. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer. 2009;9:563\u201375.","journal-title":"Nat Rev Cancer"},{"key":"1200_CR14","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1038\/s41568-018-0074-8","volume":"18","author":"D Mossmann","year":"2018","unstructured":"Mossmann D, Park S, Hall MN. mTOR signalling and cellular metabolism are mutual determinants in cancer. Nat Rev Cancer. 2018;18:744\u201357.","journal-title":"Nat Rev Cancer"},{"key":"1200_CR15","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1126\/science.1200094","volume":"332","author":"JS Oakhill","year":"2011","unstructured":"Oakhill JS, Steel R, Chen ZP, et al. AMPK is a direct adenylate charge-regulated protein kinase. Science. 2011;332:1433\u20135.","journal-title":"Science"},{"key":"1200_CR16","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1158\/2159-8290.CD-17-0151","volume":"7","author":"Consortium APG","year":"2017","unstructured":"Consortium APG. AACR project GENIE: powering precision medicine through an international consortium. Cancer Discov. 2017;7:818\u201331.","journal-title":"Cancer Discov"},{"key":"1200_CR17","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.lungcan.2010.02.004","volume":"70","author":"BC Roy","year":"2010","unstructured":"Roy BC, Kohno T, Iwakawa R, et al. Involvement of LKB1 in epithelial-mesenchymal transition (EMT) of human lung cancer cells. Lung Cancer. 2010;70:136\u201345.","journal-title":"Lung Cancer"},{"key":"1200_CR18","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.humpath.2018.08.017","volume":"83","author":"M Hu","year":"2019","unstructured":"Hu M, Zhao T, Liu J, et al. Decreased expression of LKB1 is associated with epithelial-mesenchymal transition and led to an unfavorable prognosis in gastric cancer. Hum Pathol. 2019;83:133\u20139.","journal-title":"Hum Pathol"},{"key":"1200_CR19","doi-asserted-by":"crossref","unstructured":"Paul MR, Pan TC, Pant DK et al. Genomic landscape of metastatic breast cancer identifies preferentially dysregulated pathways and targets. J Clin Invest 2020.","DOI":"10.1172\/JCI129941"},{"key":"1200_CR20","doi-asserted-by":"publisher","first-page":"5709","DOI":"10.1038\/onc.2017.164","volume":"36","author":"S Sengupta","year":"2017","unstructured":"Sengupta S, Nagalingam A, Muniraj N, et al. Activation of tumor suppressor LKB1 by honokiol abrogates cancer stem-like phenotype in breast cancer via inhibition of oncogenic Stat3. Oncogene. 2017;36:5709\u201321.","journal-title":"Oncogene"},{"key":"1200_CR21","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13046-014-0070-0","volume":"33","author":"J Li","year":"2014","unstructured":"Li J, Liu J, Li P, et al. Loss of LKB1 disrupts breast epithelial cell polarity and promotes breast cancer metastasis and invasion. J Exp Clin Cancer Res. 2014;33:70.","journal-title":"J Exp Clin Cancer Res"},{"key":"1200_CR22","doi-asserted-by":"publisher","first-page":"21374","DOI":"10.1038\/srep21374","volume":"6","author":"IC Chen","year":"2016","unstructured":"Chen IC, Chang YC, Lu YS, et al. Clinical relevance of liver kinase B1(LKB1) protein and gene expression in breast cancer. Sci Rep. 2016;6:21374.","journal-title":"Sci Rep"},{"issue":"611\u2013623","key":"1200_CR23","first-page":"e17","volume":"173","author":"TJ Mitchell","year":"2018","unstructured":"Mitchell TJ, Turajlic S, Rowan A, et al. Timing the landmark events in the evolution of clear cell renal cell cancer: TRACERx renal. Cell. 2018;173(611\u2013623):e17.","journal-title":"Cell"},{"key":"1200_CR24","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1126\/science.aau8768","volume":"368","author":"A Cipponi","year":"2020","unstructured":"Cipponi A, Goode DL, Bedo J, et al. MTOR signaling orchestrates stress-induced mutagenesis, facilitating adaptive evolution in cancer. Science. 2020;368:1127\u201331.","journal-title":"Science"},{"issue":"879\u2013893","key":"1200_CR25","first-page":"e13","volume":"173","author":"C Kim","year":"2018","unstructured":"Kim C, Gao R, Sei E, et al. Chemoresistance evolution in triple-negative breast cancer delineated by single-cell sequencing. Cell. 2018;173(879\u2013893):e13.","journal-title":"Cell"}],"container-title":["Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-020-01200-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12282-020-01200-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-020-01200-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,10]],"date-time":"2022-12-10T08:03:19Z","timestamp":1670659399000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12282-020-01200-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,2]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["1200"],"URL":"https:\/\/doi.org\/10.1007\/s12282-020-01200-1","relation":{},"ISSN":["1340-6868","1880-4233"],"issn-type":[{"value":"1340-6868","type":"print"},{"value":"1880-4233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,2]]},"assertion":[{"value":"17 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Tetsuhiro Yoshinami reports lecture fees from Chugai, Novartis, and Kyowa Kirin. Fumio Imamura reports honoraria from AstraZeneca, Chugai, Pfizer and Boehringer Ingelheim and research funds from AstraZeneca. Other authors report no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Informed consent was obtained from the present case. This study was approved by the Institutional Review Board at Osaka International Cancer Institute (No.18132).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}